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Objectives: SAGIT is a clinician-reported outcome tool designed to help endocri-
nologists describe acromegaly patients and disease activity in their everyday prac-
tice. SAGIT records five elements of the disease: Signs and symptoms (S), Associated 
comorbidities (A), GH concentration (G - either assessed as GH nadir after oral glu-
cose tolerance test or GH random or series), IGF-1 concentration (I) and Tumor (T). 
The objectives of the present work were to assess acceptability, understanding 
and possible uses of SAGIT with endocrinologists in real conditions. MethOds: 
Endocrinologists from France (n= 2), Germany (n= 1), Italy (n= 2), Spain (n= 2) and 
United States (n= 2) completed SAGIT for patients with active acromegaly (n= 9), 
controlled/stable acromegaly (n= 10) and treatment-naïve patients (n= 7). After com-
pletion of SAGIT, endocrinologist’s reported their perception and opinion of the tool 
using the PRAgmatic Content and face validity Test. Results: Endocrinologists 
had no difficulties completing the S, A, I and T elements of SAGIT and reporting the 
respective scores based on their patients’ data. Both GH nadir after oral glucose load 
and GH random or series were informed by most endocrinologists while informa-
tion for one of the two elements only is required. The majority of endocrinologists 
deemed the information retrieved from SAGIT useful, either for research purpose 
(n= 7), decision-making (n= 6), or response therapy assessment (n= 5). They found 
it concise, easy to understand and unbiased (n= 8), and simple, quick to complete 
and informative (n= 7). Scores and decision rules and interpretation were among 
the aspects that required improvement. Scores of each elements of SAGIT vary 
according to patient’s acromegaly status. cOnclusiOns: Face and content validity 
of SAGIT are demonstrated, as is its applicability in clinical practice and research. It 
seems a promising tool for staging and classifying acromegaly patients. The planned 
validation study will allow the definition of scoring rules, interpretation and recom-
mendations for managing patients in clinical practice.
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Objectives: To synthesize the available information on the therapeutic value of 
dipeptidyl peptidase-4 inhibitors (DPP-4) for the treatment of type 2 diabetes mellitus 
(T2DM) from the point of view of the patient-reported outcomes (PROs). MethOds: 
A systematic review was performed on International (Pub Med, WOK, Scopus, 
Cochrane Library) and Spanish (IBECS, MEDES) databases. Observational studies and 
narrative or systematic reviews regarding T2DM patients and use of DPP-4 inhibitors 
until June 2013 were selected. Results: We identified 1,713 publications; 317 were 
excluded after duplicate review, 1,383 by title/abstract review and 9 after applying 
inclusion criteria (n= 9). A total of 4 studies conducted in Italy (n= 1), Germany (n= 1), 
USA (n= 1), and one international (including Spain) were selected. Three publications 
had a retrospective design and 1 was prospective. Two studies reported information 
about adherence/persistence, one about satisfaction and one about preferences. No 
information about HRQoL was identified. Patients receiving DPP-4 inhibitors were 
more likely to be adherent than those treated with Glucagon-like peptide-1 (GLP-1) 
agonists [Odds Ratio= 0.40; 95% CI= 0.37-0.42], sulfonylurea [OR= 0.49; 95% CI= 0.46-
0.52] or thiazolidinediones [OR= 0.54; 95% CI= 0.51-0.57]; moreover, DPP-4 inhibitors 
were associated with a lower risk of treatment discontinuation [Hazard Ratio= 0.74; 
95% CI= 0.71-0.76], explained by a greater tolerability and a lower risk of hypoglyce-
mia. Combination of DPP-4 inhibitors and metformin increased patient’s satisfac-
tion by a 30%, associated with higher control of glucose levels. Most of the patients 
preferred DPP-4 inhibitors to GLP-1 agonists (85% vs. 15%; p< 0.001) as first option. In 
the Spanish population, the proportion of patients preferring DPP-4 inhibitors was 
even higher (90.4% vs. 9.6%; p< 0.001). cOnclusiOns: PROs in DPP-4 inhibitors are 
poorly described in the literature. Nevertheless DPP-4 inhibitors are preferred as first 
option and are associated with higher persistence and satisfaction, mainly due to 
higher perception of glycemic control of glucose level and lower hypoglycemia risk.
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Objectives: The objective of the study is to assess the cost of continuous sub-
cutaneous insulin infusion (CSII) application for children with diabetes type 1 in 
Sofia, Bulgaria and to compare the changes in BMI and HbA (1c), of three groups of 
children- with diabetes – applying insulin pens with human insulin, with analog 
insulin and children with insulin pumps. MethOds: The study was performed from 
the point of view of the health insurance fund and patients. The data collected from 
the patients’ dossier including demographics about their age, sex, weight, duration 
of disease and HbA (1c) and type of treatment (CSII or analogue insulin treatment 
with a pen device). Cost of CSII, blood glucose monitoring system and strips was 
calculated. The primary outcome observed was the variation in HbA (1c) and the 
secondary was the BMI change. 51 children were observed. The data collected from 
the patients’ dossier including demographics about their age, sex, weight, duration 
of disease and HbA (1c) and type of treatment (CSII or analogue insulin treatment 
with a pen device). Results: The total yearly cost weighed with the duration of 
the disease is 1850 Euro (30% reimbursed). The average improvement of HbA (1c) 
after the CSII introduction is 1.72 and the average BMI was 37.03. cOnclusiOns: 
Improvements in glycemic control associated with CSII led to reduced HbA (1c) 
reported here. Results: Overall, 1,038 respondents (T1DM= 466, T2DM= 572) com-
pleted 3,528 questionnaires. Mean insulin treatment duration was 11.7 years and 
mean HbA1c was 8.2% (66.2 mmol/mol). Mean NSHE/week was 2.4 (T1DM) and 0.8 
(T2DM); 23% (T1DM) and 26% (T2DM) occurred at night. Fatigue and reduced alert-
ness were the commonest sequelae of NSHEs (78% and 51% of respondents, respec-
tively). Effects of nocturnal NSHEs lasted significantly longer than effects of daytime 
events: T1DM= 10.6 vs. 4.9 hours (p= 0.0002); T2DM= 15.3 vs. 5.1 hours (p< 0.0001). 
In the week following a NSHE, blood glucose testing increased 12% (T1DM) and 
21% (T2DM). In employed respondents (47% of total), 20% of NSHEs caused loss of 
work-time, which was longer following nocturnal NSHEs: T1DM= 2.7 vs. 1.1 hours 
(p= 0.0184); T2DM= 2.5 vs. 1.6 hours (p= 0.1340). Over a third of employed respond-
ents experienced difficulty concentrating at work following NSHEs (T1DM= 39%; 
T2DM= 44%). Respondents contacted a health care professional (HCP) after 3% 
(T1DM) and 7% (T2DM) of NSHEs. Overall, respondents rarely or never informed 
HCPs about NSHEs (T1DM= 82%; T2DM= 69%). cOnclusiOns: NSHEs are common 
in adults with insulin-treated diabetes in the UK, and have a negative impact on 
personal well-being, work productivity, and health care resource use. As they are 
seldom reported to HCPs, the burden of hypoglycaemia may be underestimated.
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Objectives: The aim of the empirical study is to evaluate patients’ preferences for 
different characteristics of treatment in type2 diabetes mellitus (T2DM). As T2DM 
treatment asks for strict adherence, patient’s needs and preferences should be taken 
into consideration. MethOds: Based on a qualitative and quantitative analysis 
a Discrete Choice Experiment (DCE) was applied to identify patient preferences. 
Apart from six identical attributes (adjustment of glycated hemoglobin [HbA1c], 
prevention of hypoglycemia, risk of genital infection, risk of gastrointestinal prob-
lems, risk of urinary tract infection and weight change) one continuous variable of 
either healthy life years equivalents (HYE) or money equivalents (ME) was included. 
The DCE was conducted using a fractional factorial design and the statistical data 
analysis used random effect logit models. Results: In total N= 626 (N= 318 HYE + 
N= 308 ME) T2DM patients participated in the survey. The estimation revealed a clear 
dominance for prevention of hypoglycemia (coefficient: 0,937) and adjustment of 
HbA1c (coefficient: 0,541). The attributes, additional healthy life years (coefficient: 
0,458) or additional cost (coefficient: 0,420) were in the middle rank and both of 
significant impact. The side effects, risk of genital infection (coefficient: 0,301), risk 
of gastrointestinal problems (coefficient: 0,296) and risk of urinary tract infection 
(coefficient: 0,241) followed in this order. Possible weight change (coefficient: 0,047) 
was of less importance (last rank) to the patients in this evaluation. cOnclusiOns: 
These survey results demonstrate how much a treatment characteristic of a (hypo-
thetical) oral diabetes treatment affects the treatment decision Understanding how 
patients perceive and value different aspects of oral T2DM treatment is vital to the 
optimal design and evaluation of treatment options. (IB 209403011/14).
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Objectives: Only a few studies have explored deriving clinically relevant time-
equivalents in comparison to money-equivalents from Discrete-Choice Experiment 
(DCE) data. By separating the decision model and including a) healthy life-years 
equivalents (HYEsurvey) or b) money equivalents (MEsurvey) it could be derived 
if both lead to similar preference patterns and allow answering the question: Can 
HYE or ME serve as identical “currency” for patients with type2 diabetes mellitus 
(T2DM) patients? MethOds: A DCE, separated into two versions, was applied to 
identify patient preferences in oral diabetes treatment. Six identical attributes and 
one continuous variable of either HYE or ME were included. To be able to test the 
rescaling effect a scope test has been included, by using different level ranges of 
the time/money attribute. DCE used a fractional factorial design and random effect-
logit-models (Stata, xtlogit and gllamm). Results: The estimation of the N= 626 
(N= 318HYE+N= 308ME) datasets of T2DM patients revealed similar preference pat-
terns for both survey version were prevention of hypoglycemia (coefficient. HYE: 
0,937; coefficient. ME: 0,847) and adjustment of hemoglobin A1c (HbA1c) (coefficient. 
HYE: 0,541; coefficient. ME: 0,649) occurred on first rank. Additional healthy life years 
(coefficient. HYE: 0,458) or additional cost (coefficient. ME: 0,420) ranked in middle 
positions. Side effects of risk of genital infection (coefficient. HYE: 0,301; coefficient. 
ME: 0,416), risk of gastrointestinal problems (coefficient. HYE: 0,296; coefficient. ME: 
0,408) and risk of urinary tract infection (coefficient. HYE: 0,241; coefficient. ME: 
0,355) followed accordingly. Possible weight change (coefficient. HYE: 0,047; coef-
ficient. ME: 0,067) showed no significant effect in this evaluation. cOnclusiOns: 
For the first time the methods of HYE and ME were used in one study to be able to 
compare patients’ preferences regarding those two continuous currencies (HYE/
ME) of treatment in T2DM, as well as the influence of those criteria on the patient 
decision patterns and patient benefit. Therefore, as HYE and ME led to comparable 
preference patterns, both can be discussed as summary measures of health out-
come, in interchangeable ways, but further research is needed. (IB 209203011/14)
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